Suheung Co., Ltd. (008490.KS)
KRW 12880.0
(-1.68%)
KRW 12880.0
(-1.68%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 42.99 Billion KRW | -30.63% |
| 2022 | 61.97 Billion KRW | -10.96% |
| 2021 | 69.6 Billion KRW | -6.34% |
| 2020 | 74.31 Billion KRW | 56.77% |
| 2019 | 47.4 Billion KRW | 20.6% |
| 2018 | 39.3 Billion KRW | 5.42% |
| 2017 | 37.28 Billion KRW | -7.05% |
| 2016 | 40.11 Billion KRW | 18.56% |
| 2015 | 33.83 Billion KRW | 16.15% |
| 2014 | 29.12 Billion KRW | 15.79% |
| 2013 | 25.15 Billion KRW | 74.38% |
| 2012 | 14.42 Billion KRW | -46.39% |
| 2011 | 26.9 Billion KRW | -7.36% |
| 2010 | 29.04 Billion KRW | 18.7% |
| 2009 | 24.47 Billion KRW | 23.8% |
| 2008 | 19.76 Billion KRW | 59.99% |
| 2007 | 12.35 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 10.86 Billion KRW | -8.68% |
| 2024 Q1 | 11.99 Billion KRW | 199.21% |
| 2023 Q4 | 4.01 Billion KRW | -57.51% |
| 2023 FY | 42.99 Billion KRW | -30.63% |
| 2023 Q1 | 13.2 Billion KRW | 421.06% |
| 2023 Q2 | 16.34 Billion KRW | 23.74% |
| 2023 Q3 | 9.43 Billion KRW | -42.23% |
| 2022 Q2 | 18.38 Billion KRW | 2.38% |
| 2022 Q3 | 18.87 Billion KRW | 2.65% |
| 2022 Q4 | 2.53 Billion KRW | -86.57% |
| 2022 Q1 | 17.95 Billion KRW | 45.62% |
| 2022 FY | 61.97 Billion KRW | -10.96% |
| 2021 Q3 | 11.73 Billion KRW | -48.98% |
| 2021 Q4 | 12.33 Billion KRW | 5.05% |
| 2021 FY | 69.6 Billion KRW | -6.34% |
| 2021 Q1 | 22.52 Billion KRW | 53.62% |
| 2021 Q2 | 23 Billion KRW | 2.16% |
| 2020 Q1 | 18.51 Billion KRW | 110.62% |
| 2020 FY | 74.31 Billion KRW | 56.77% |
| 2020 Q4 | 14.66 Billion KRW | -26.26% |
| 2020 Q3 | 19.88 Billion KRW | -6.74% |
| 2020 Q2 | 21.31 Billion KRW | 15.14% |
| 2019 FY | 47.4 Billion KRW | 20.6% |
| 2019 Q4 | 8.79 Billion KRW | -29.53% |
| 2019 Q3 | 12.47 Billion KRW | -8.43% |
| 2019 Q1 | 12.51 Billion KRW | 39.5% |
| 2019 Q2 | 13.62 Billion KRW | 8.81% |
| 2018 Q2 | 12.02 Billion KRW | 16.83% |
| 2018 Q3 | 8.02 Billion KRW | -33.25% |
| 2018 Q4 | 8.97 Billion KRW | 11.84% |
| 2018 FY | 39.3 Billion KRW | 5.42% |
| 2018 Q1 | 10.28 Billion KRW | 41.63% |
| 2017 FY | 37.28 Billion KRW | -7.05% |
| 2017 Q4 | 7.26 Billion KRW | -21.99% |
| 2017 Q3 | 9.31 Billion KRW | -13.1% |
| 2017 Q2 | 10.71 Billion KRW | 7.2% |
| 2017 Q1 | 9.99 Billion KRW | 21.33% |
| 2016 FY | 40.11 Billion KRW | 18.56% |
| 2016 Q4 | 8.23 Billion KRW | -23.37% |
| 2016 Q3 | 10.75 Billion KRW | -10.33% |
| 2016 Q2 | 11.99 Billion KRW | 31.27% |
| 2016 Q1 | 9.13 Billion KRW | 30.38% |
| 2015 Q3 | 8.01 Billion KRW | -20.14% |
| 2015 FY | 33.83 Billion KRW | 16.15% |
| 2015 Q1 | 8.76 Billion KRW | 59.62% |
| 2015 Q2 | 10.04 Billion KRW | 14.55% |
| 2015 Q4 | 7 Billion KRW | -12.64% |
| 2014 FY | 29.12 Billion KRW | 15.79% |
| 2014 Q4 | 5.49 Billion KRW | -32.64% |
| 2014 Q3 | 8.15 Billion KRW | -5.63% |
| 2014 Q2 | 8.64 Billion KRW | 26.29% |
| 2014 Q1 | 6.84 Billion KRW | 20.49% |
| 2013 Q1 | 5.19 Billion KRW | 142.11% |
| 2013 Q2 | 8.86 Billion KRW | 70.64% |
| 2013 FY | 25.15 Billion KRW | 74.38% |
| 2013 Q4 | 5.67 Billion KRW | 4.69% |
| 2013 Q3 | 5.42 Billion KRW | -38.78% |
| 2012 Q3 | 2.09 Billion KRW | -58.39% |
| 2012 Q2 | 5.03 Billion KRW | 127.99% |
| 2012 Q4 | 2.14 Billion KRW | 2.38% |
| 2012 FY | 14.42 Billion KRW | -46.39% |
| 2012 Q1 | 2.2 Billion KRW | 0.0% |
| 2011 Q2 | 6.73 Billion KRW | 23.44% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 26.9 Billion KRW | -7.36% |
| 2011 Q1 | 5.45 Billion KRW | 0.0% |
| 2011 Q3 | 4.54 Billion KRW | -32.43% |
| 2010 Q2 | 6.22 Billion KRW | 81.31% |
| 2010 FY | 29.04 Billion KRW | 18.7% |
| 2010 Q1 | 3.43 Billion KRW | 0.0% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q3 | 4.46 Billion KRW | -28.25% |
| 2009 Q2 | 6.3 Billion KRW | 26.13% |
| 2009 Q1 | 4.99 Billion KRW | 0.0% |
| 2009 FY | 24.47 Billion KRW | 23.8% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 Q3 | 3.77 Billion KRW | -40.12% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 FY | 19.76 Billion KRW | 59.99% |
| 2008 Q2 | 4.67 Billion KRW | 79.5% |
| 2008 Q3 | 3.44 Billion KRW | -26.26% |
| 2008 Q1 | 2.6 Billion KRW | 0.0% |
| 2007 Q4 | - KRW | -100.0% |
| 2007 FY | 12.35 Billion KRW | 0.0% |
| 2007 Q3 | 2.86 Billion KRW | -23.67% |
| 2007 Q1 | 1.77 Billion KRW | 0.0% |
| 2007 Q2 | 3.75 Billion KRW | 111.4% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | -11694.402% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 44.076% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 154.04% |
| HANDOK Inc. | 12.57 Billion KRW | -241.804% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 2261.482% |
| Yuhan Corporation | 74.56 Billion KRW | 42.337% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | -284.623% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 338.298% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 80.881% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | -1306.876% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -199.608% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | -7109.049% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | -4361.145% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | -59.055% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -11694.402% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 654.341% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | -965.913% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 161.465% |
| JW Holdings Corporation | 143.66 Billion KRW | 70.073% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 180.488% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 82.565% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 57.135% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 190.721% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | -520.693% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | -564.423% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | -392.419% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -11694.402% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | 11.837% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 67.772% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 57.135% |
| Yuhan Corporation | 74.56 Billion KRW | 42.337% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | -105.519% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | -1279.196% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 57.135% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | -109.892% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 21.756% |
| CKD Bio Corp. | -20.15 Billion KRW | 313.348% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | -33.389% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | -69.927% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | -32.19% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 190.721% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | -29.711% |
| Boryung Corporation | 68.26 Billion KRW | 37.019% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 214.663% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -199.608% |
| JW Lifescience Corporation | 32.09 Billion KRW | -33.976% |